Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1150MR)

This product GTTS-WQ1150MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1150MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2050MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ10622MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ11147MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ12954MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ7669MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ755MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ9113MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ15790MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW